share_log

DEF 14A: Definitive information statements

DEF 14A: Definitive information statements

DEF 14A：股东委托书决议
美股sec公告 ·  05/03 08:05
Moomoo AI 已提取核心信息
SeaStar Medical Holding Corporation (SeaStar Medical) has announced the filing of a definitive proxy statement (DEF 14A) with the U.S. Securities and Exchange Commission (SEC) for its 2024 Annual Meeting of Stockholders. The meeting is scheduled for June 4, 2024, at 10:00 a.m. Mountain Time and will be held virtually. The proxy statement details the matters to be presented at the meeting, including the election of three Class II Directors, the approval of an amendment to the company's 2022 Omnibus Equity Incentive Plan to increase authorized shares, the approval of the issuance of 20% or more of the company's outstanding shares of Common Stock upon exercise of Series A and Series B Warrants, and the ratification of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The notice also includes instructions for stockholders on how to vote and attend the meeting online. Eric Schlorff, Director and CEO of SeaStar Medical, has urged stockholders to vote promptly, highlighting the importance of their votes being represented.
SeaStar Medical Holding Corporation (SeaStar Medical) has announced the filing of a definitive proxy statement (DEF 14A) with the U.S. Securities and Exchange Commission (SEC) for its 2024 Annual Meeting of Stockholders. The meeting is scheduled for June 4, 2024, at 10:00 a.m. Mountain Time and will be held virtually. The proxy statement details the matters to be presented at the meeting, including the election of three Class II Directors, the approval of an amendment to the company's 2022 Omnibus Equity Incentive Plan to increase authorized shares, the approval of the issuance of 20% or more of the company's outstanding shares of Common Stock upon exercise of Series A and Series B Warrants, and the ratification of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The notice also includes instructions for stockholders on how to vote and attend the meeting online. Eric Schlorff, Director and CEO of SeaStar Medical, has urged stockholders to vote promptly, highlighting the importance of their votes being represented.
海星医疗控股公司（SeaStar Medical）宣布向美国证券交易委员会（SEC）提交其2024年年度股东大会的最终委托书（DEF 14A）。会议定于山区时间2024年6月4日上午10点举行，将以虚拟方式举行。委托书详细说明了将在会议上提出的事项，包括选举三名二类董事，批准公司2022年综合股权激励计划的修正案，以增加法定股份，批准在行使A系列和B系列认股权证时发行公司20％或以上的已发行普通股，以及批准WithumSmith+Brown, PC 作为截至12月的财政年度的独立注册会计师事务所 2024 年 31 日。该通知还包括股东如何在线投票和参加会议的说明。SeaStar Medical董事兼首席执行官埃里克·施洛夫敦促股东迅速投票，强调了代表他们的选票的重要性。
海星医疗控股公司（SeaStar Medical）宣布向美国证券交易委员会（SEC）提交其2024年年度股东大会的最终委托书（DEF 14A）。会议定于山区时间2024年6月4日上午10点举行，将以虚拟方式举行。委托书详细说明了将在会议上提出的事项，包括选举三名二类董事，批准公司2022年综合股权激励计划的修正案，以增加法定股份，批准在行使A系列和B系列认股权证时发行公司20％或以上的已发行普通股，以及批准WithumSmith+Brown, PC 作为截至12月的财政年度的独立注册会计师事务所 2024 年 31 日。该通知还包括股东如何在线投票和参加会议的说明。SeaStar Medical董事兼首席执行官埃里克·施洛夫敦促股东迅速投票，强调了代表他们的选票的重要性。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息